Sufficient-dose Brentuximab vedotin improves prognosis in patients with classic Hodgkin lymphoma: a single-center real-world study in China - Top-Institutions - MDSpire

Sufficient-dose Brentuximab vedotin improves prognosis in patients with classic Hodgkin lymphoma: a single-center real-world study in China

  • By

  • Zhangyuting He

  • Huiying Zhu

  • Chong Wei

  • Danqing Zhao

  • Jing Ruan

  • Wei Zhang

  • Daobin Zhou

  • Yan Zhang

  • July 6, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology

  • #2

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology
    • Oncology

  • #3

    City of Hope Medical Center
    City of Hope Medical Center

    Duarte, CA

    Key Differentiators

    • Hematology
    • Oncology

  • #4

    Peking Union Medical College Hospital
    Peking Union Medical College Hospital

    Beijing, BJ

    Key Differentiators

    • Hematology

Original Source(s)

Sufficient-dose Brentuximab vedotin improves prognosis in patients with classic Hodgkin lymphoma: a single-center real-world study in China

  • by Zhangyuting He, Huiying Zhu, Chong Wei, Danqing Zhao, Jing Ruan, Wei Zhang, Daobin Zhou, Yan Zhang

  • July 6, 2026

Related Content

Head and neck squamous cell carcinoma with femoral metastasis: a case report and systematic review of current literature

Influence of age, body mass index and family income on the health Quality of Life among the breast cancer patients in Bangladesh: a cross-sectional study

The effects of brain radiotherapy combined with immunotherapy and chemotherapy for driver gene-negative non-small-cell lung cancer with brain metastases